The Timing of P2Y12 Inhibitor Initiation in the Treatment of ACS? Does the Evidence Exist in This Era?

Harsh Golwala, Deepak L. Bhatt

Research output: Contribution to journal › Review article

3 Citations (Scopus)

Abstract

The majority of acute coronary syndromes (ACS) are well characterized as a consequence of plaque rupture and subsequent thrombosis. Antiplatelet agents targeting inhibition of P2Y12 receptors on the platelets have been shown to reduce future risk of cardiovascular events in this patient population. However, the timing of initiation of these agents, in particular, in patients managed with an invasive strategy with percutaneous coronary interventions (PCI) is debatable. The data supporting pretreatment with antiplatelet agents prior to PCI in ACS patients date to trials performed >15 years ago, wherein the time to PCI was >5 days, and hence, the utility of pretreatment with these agents in the contemporary era remains uncertain. In addition, newer antiplatelet agents such as prasugrel, ticagrelor, and cangrelor with rapid onset of action, pose a challenge for justification of oral antiplatelet pretreatment in patients with ACS. In this review article, we will discuss the pharmacokinetic properties of four different antiplatelet agents (clopidogrel, prasugrel, ticagrelor, cangrelor), as well as major randomized clinical trials assessing safety and efficacy of their role as pretreatment agents in patients presenting with ACS.

Original languageEnglish (US)
Pages (from-to)471-477
Number of pages7
JournalProgress in Cardiovascular Diseases
Volume60
Issue number4-5
DOIs
StatePublished - Jan 1 2018
Externally publishedYes

Fingerprint

Platelet Aggregation Inhibitors
Acute Coronary Syndrome
Percutaneous Coronary Intervention
clopidogrel
Proxy
Therapeutics
Rupture
Thrombosis
Blood Platelets
Randomized Controlled Trials
Pharmacokinetics
Safety
Population
Prasugrel Hydrochloride
Ticagrelor
cangrelor

Keywords

  • Acute coronary syndromes
  • Antiplatelet therapy
  • P2Y inhibitors
  • Pretreatment

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

The Timing of P2Y12 Inhibitor Initiation in the Treatment of ACS? Does the Evidence Exist in This Era? / Golwala, Harsh; Bhatt, Deepak L.

In: Progress in Cardiovascular Diseases, Vol. 60, No. 4-5, 01.01.2018, p. 471-477.

Research output: Contribution to journal › Review article

Golwala, H & Bhatt, DL 2018, 'The Timing of P2Y12 Inhibitor Initiation in the Treatment of ACS? Does the Evidence Exist in This Era?', Progress in Cardiovascular Diseases, vol. 60, no. 4-5, pp. 471-477. https://doi.org/10.1016/j.pcad.2018.01.001
Golwala H, Bhatt DL. The Timing of P2Y12 Inhibitor Initiation in the Treatment of ACS? Does the Evidence Exist in This Era? Progress in Cardiovascular Diseases. 2018 Jan 1;60(4-5):471-477. https://doi.org/10.1016/j.pcad.2018.01.001
Golwala, Harsh ; Bhatt, Deepak L. / The Timing of P2Y12 Inhibitor Initiation in the Treatment of ACS? Does the Evidence Exist in This Era?. In: Progress in Cardiovascular Diseases. 2018 ; Vol. 60, No. 4-5. pp. 471-477.
@article{2a72c608c5cf412ebea0d9c90926213e,
title = "The Timing of P2Y12 Inhibitor Initiation in the Treatment of ACS? Does the Evidence Exist in This Era?",
abstract = "The majority of acute coronary syndromes (ACS) are well characterized as a consequence of plaque rupture and subsequent thrombosis. Antiplatelet agents targeting inhibition of P2Y12 receptors on the platelets have been shown to reduce future risk of cardiovascular events in this patient population. However, the timing of initiation of these agents, in particular, in patients managed with an invasive strategy with percutaneous coronary interventions (PCI) is debatable. The data supporting pretreatment with antiplatelet agents prior to PCI in ACS patients date to trials performed >15 years ago, wherein the time to PCI was >5 days, and hence, the utility of pretreatment with these agents in the contemporary era remains uncertain. In addition, newer antiplatelet agents such as prasugrel, ticagrelor, and cangrelor with rapid onset of action, pose a challenge for justification of oral antiplatelet pretreatment in patients with ACS. In this review article, we will discuss the pharmacokinetic properties of four different antiplatelet agents (clopidogrel, prasugrel, ticagrelor, cangrelor), as well as major randomized clinical trials assessing safety and efficacy of their role as pretreatment agents in patients presenting with ACS.",
keywords = "Acute coronary syndromes, Antiplatelet therapy, P2Y inhibitors, Pretreatment",
author = "Harsh Golwala and Bhatt, {Deepak L.}",
year = "2018",
month = "1",
day = "1",
doi = "10.1016/j.pcad.2018.01.001",
language = "English (US)",
volume = "60",
pages = "471--477",
journal = "Progress in Cardiovascular Diseases",
issn = "0033-0620",
publisher = "W.B. Saunders Ltd",
number = "4-5",

}

TY - JOUR

T1 - The Timing of P2Y12 Inhibitor Initiation in the Treatment of ACS? Does the Evidence Exist in This Era?

AU - Golwala, Harsh

AU - Bhatt, Deepak L.

PY - 2018/1/1

Y1 - 2018/1/1

N2 - The majority of acute coronary syndromes (ACS) are well characterized as a consequence of plaque rupture and subsequent thrombosis. Antiplatelet agents targeting inhibition of P2Y12 receptors on the platelets have been shown to reduce future risk of cardiovascular events in this patient population. However, the timing of initiation of these agents, in particular, in patients managed with an invasive strategy with percutaneous coronary interventions (PCI) is debatable. The data supporting pretreatment with antiplatelet agents prior to PCI in ACS patients date to trials performed >15 years ago, wherein the time to PCI was >5 days, and hence, the utility of pretreatment with these agents in the contemporary era remains uncertain. In addition, newer antiplatelet agents such as prasugrel, ticagrelor, and cangrelor with rapid onset of action, pose a challenge for justification of oral antiplatelet pretreatment in patients with ACS. In this review article, we will discuss the pharmacokinetic properties of four different antiplatelet agents (clopidogrel, prasugrel, ticagrelor, cangrelor), as well as major randomized clinical trials assessing safety and efficacy of their role as pretreatment agents in patients presenting with ACS.

AB - The majority of acute coronary syndromes (ACS) are well characterized as a consequence of plaque rupture and subsequent thrombosis. Antiplatelet agents targeting inhibition of P2Y12 receptors on the platelets have been shown to reduce future risk of cardiovascular events in this patient population. However, the timing of initiation of these agents, in particular, in patients managed with an invasive strategy with percutaneous coronary interventions (PCI) is debatable. The data supporting pretreatment with antiplatelet agents prior to PCI in ACS patients date to trials performed >15 years ago, wherein the time to PCI was >5 days, and hence, the utility of pretreatment with these agents in the contemporary era remains uncertain. In addition, newer antiplatelet agents such as prasugrel, ticagrelor, and cangrelor with rapid onset of action, pose a challenge for justification of oral antiplatelet pretreatment in patients with ACS. In this review article, we will discuss the pharmacokinetic properties of four different antiplatelet agents (clopidogrel, prasugrel, ticagrelor, cangrelor), as well as major randomized clinical trials assessing safety and efficacy of their role as pretreatment agents in patients presenting with ACS.

KW - Acute coronary syndromes

KW - Antiplatelet therapy

KW - P2Y inhibitors

KW - Pretreatment

UR - http://www.scopus.com/inward/record.url?scp=85041661439&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85041661439&partnerID=8YFLogxK

U2 - 10.1016/j.pcad.2018.01.001

DO - 10.1016/j.pcad.2018.01.001

M3 - Review article

C2 - 29339169

AN - SCOPUS:85041661439

VL - 60

SP - 471

EP - 477

JO - Progress in Cardiovascular Diseases

JF - Progress in Cardiovascular Diseases

SN - 0033-0620

IS - 4-5

ER -

Access to Document